Universal Vision Biotechnology Co., Ltd. (TPEX:3218)

Paramount Global Ratios and Metrics

Market cap in millions TWD. Fiscal year is January - December.

Fiscal Year	Current	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Aug 8, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Market Capitalization	17,453	16,945	23,469	23,859	21,543	18,193
Market Cap Growth	-27.07%	-27.80%	-1.64%	10.75%	18.41%	254.07%
Enterprise Value	16,203	16,391	23,062	23,751	21,599	18,004
Last Close Price	206.00	193.42	260.68	260.58	230.89	192.22
PE Ratio	15.58	15.92	22.46	28.05	36.18	37.65
Forward PE	14.21	12.81	12.81	12.81	12.81	12.81
PS Ratio	4.08	4.01	5.75	6.83	8.19	8.86
PB Ratio	4.99	4.51	7.02	8.43	9.25	8.92
P/TBV Ratio	5.24	4.71	7.44	9.04	9.97	9.64
P/FCF Ratio	13.13	13.69	21.71	30.65	36.68	34.20
P/OCF Ratio	9.82	10.13	15.11	18.81	23.63	22.00
EV/Sales Ratio	3.79	3.88	5.65	6.80	8.21	8.77
EV/EBITDA Ratio	8.29	9.43	14.49	18.34	22.91	24.33
EV/EBIT Ratio	11.39	11.73	17.58	21.97	28.10	30.18
EV/FCF Ratio	12.19	13.25	21.33	30.51	36.77	33.85
Debt / Equity Ratio	0.28	0.28	0.23	0.28	0.33	0.30
Debt / EBITDA Ratio	0.50	0.55	0.44	0.54	0.71	0.72
Debt / FCF Ratio	0.73	0.85	0.72	1.01	1.31	1.16
Asset Turnover	0.74	0.78	0.85	0.85	0.76	0.71
Inventory Turnover	5.97	5.80	6.26	7.89	11.17	12.71
Quick Ratio	1.58	2.29	2.18	2.05	2.17	1.98
Current Ratio	1.78	2.61	2.52	2.37	2.43	2.18
Return on Equity (ROE)	34.52%	29.59%	34.48%	33.66%	27.96%	25.93%
Return on Assets (ROA)	15.34%	16.04%	17.02%	16.37%	13.88%	12.82%
Return on Capital (ROIC)	21.52%	19.56%	21.20%	20.14%	16.71%	15.12%
Return on Capital Employed (ROCE)	32.50%	29.90%	31.90%	30.10%	25.50%	24.70%
Earnings Yield	6.44%	6.28%	4.45%	3.56%	2.76%	2.66%
FCF Yield	7.61%	7.30%	4.61%	3.26%	2.73%	2.92%
Dividend Yield	3.58%	3.88%	2.69%	2.17%	1.95%	1.96%
Payout Ratio	52.79%	55.70%	45.89%	44.75%	53.70%	31.51%
Buyback Yield / Dilution	-0.08%	-0.08%	-0.04%	-0.03%	0.03%	0.10%
Total Shareholder Return	3.50%	3.80%	2.64%	2.14%	1.98%	2.06%

Source: S&P Global Market Intelligence. Standard template. Financial Sources.